Legal Representation
Attorney
Susan Neuberger Weller
USPTO Deadlines
Next Deadline
1441 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2019-06-18)
Due Date
June 18, 2029
Grace Period Ends
December 18, 2029
Application History
23 events| Date | Code | Type | Description |
|---|---|---|---|
| Jan 1, 2025 | NA85 | E | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED |
| Jan 1, 2025 | C15A | O | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. |
| Jan 1, 2025 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Aug 1, 2024 | E815 | I | TEAS SECTION 8 & 15 RECEIVED |
| Jun 18, 2024 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| Jul 20, 2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jul 20, 2021 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Jul 20, 2021 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jun 18, 2019 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Apr 2, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Apr 2, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Mar 13, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Feb 22, 2019 | ALIE | A | ASSIGNED TO LIE |
| Feb 6, 2019 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jan 31, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jan 31, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jan 31, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Aug 13, 2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Aug 13, 2018 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Aug 13, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Aug 4, 2018 | DOCK | D | ASSIGNED TO EXAMINER |
| Apr 23, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Apr 19, 2018 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 042
Research and development services in the field of pharmaceuticals for the treatment of attention deficit/hyperactivity disorder (ADHD); conducting clinical trials for others in the field of pharmaceuticals for the treatment of attention- deficit/hyperactivity disorder (ADHD)
First Use Anywhere:
Jun 1, 2014
First Use in Commerce:
Jun 1, 2014
Classification
International Classes
042